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Abstract
Although angiogenesis has been proposed as a therapeutic target for the treatment of ovarian granulosa cell tumor
(GCT), its potential has not been evaluated in controlled studies. To do so, we used the Ptentm1Hwu/tm1Hwu;
Ctnnb1tm1Mmt/+;Amhr2tm3(cre)Bhr/+ (PCA) mouse model, which develops GCTs that mimic the advanced disease
in women. A monoclonal anti–vascular endothelial growth factor A (VEGFA) antibody was administered weekly
to PCA mice beginning at 3 weeks of age. By 6 weeks of age, anti-VEGFA therapy significantly decreased tumor
weights relative to controls (P < .05) and increased survival, with all treated animals but none of the controls sur-
viving to 8 weeks of age. Analyses of PCA tumors showed that anti-VEGFA treatment resulted in significant de-
creases in tumor cell proliferation and microvessel density relative to controls (P < .05). However, treatment did
not have a significant effect on apoptosis or tumor necrosis. The VEGFA receptor 2 (VEGFR2) signaling effector
p44/p42 mitogen-activated protein kinase (MAPK), whose activity is associated with cell proliferation, was signifi-
cantly less phosphorylated (i.e., activated) in tumors from the treated group (P < .05). Conversely, no significant
difference was found in the activation of protein kinase B, a VEGFR2 signaling effector associated with cell survival.
Together, these results suggest that anti-VEGFA therapy is effective at inhibiting GCT growth in the PCA model
and acts by reducing microvascular density and cell proliferation through inhibition of the VEGFR2-MAPK pathway.
Findings from this preclinical model therefore support the investigation of targeting VEGFA for the adjuvant treat-
ment of GCT in women.
Translational Oncology (2013) 6, 226–233
Introduction
The granulosa cell tumor (GCT) is the most prevalent of the sex
cord/stromal subgroup of ovarian tumors in women and is thought
to represent up to 5% of all ovarian cancers [1–4]. Although GCT is
often characterized as a low-grade malignancy [5,6], approximately
80% of patients with stage III or IV tumors die from recurrent disease
[7]. Furthermore, a large proportion of patients develop recurrences as
late as 40 years after the initial diagnosis and treatment [8], and there-
fore, fastidious long-term follow-up is required [1,3,9]. Despite the
importance and insidiousness of GCT, it has received very little atten-
tion from the cancer research community, particularly relative to the
more prevalent ovarian epithelial tumors. Perhaps as a consequence of
this, the development of therapeutic approaches for GCT has lagged
well behind other forms of ovarian cancer. Initial management of GCTs
involves cytoreductive surgery, and in cases of recurrence or advanced
disease, adjuvant treatment is frequently attempted [1,3–5,9,10]. These
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adjuvant treatments have included chemotherapy, radiotherapy,
hormonal therapy, and more recently, anti-angiogenic therapy
[1,3,4,9,10]. Studies aiming to evaluate current adjuvant treatment
protocols for GCTs in women have been limited to retrospective
studies and case reports, and no well-designed randomized studies have
been conducted to determine if any such regimen actually confers a
survival advantage [4,5,11–13].
Among the potential therapeutic targets that have been proposed
for the development of novel treatments for GCT [14–16], angio-
genesis would appear to be particularly promising. GCTs are highly
vascularized tumors, and angiogenesis is suspected to play an impor-
tant role in their development and progression [4,17,18]. Vascular
endothelial growth factor A (VEGFA) is a key mediator of angiogenesis
and is implicated in endothelial cell proliferation, migration, survival,
and vascular permeability [18–21]. VEGFA is overexpressed in 94%
of GCTs [2], and its main receptor, VEGFR2, is expressed at high
levels in 82% of primary and recurrent GCTs in both endothelial
and granulosa cells [18]. VEGF was shown to be produced by endo-
thelial as well as granulosa tumor cells [17]. In addition, VEGFA also
has well-established pro-proliferative and cytoprotective functions in
normal granulosa cells [22–24] and could therefore serve to promote
GCT cell proliferation and suppress apoptosis, in addition to pro-
moting angiogenesis. Collectively, these data suggest a very strong
potential for VEGFA as a therapeutic target for GCT.
Avastin (bevacizumab) is a recombinant humanized monoclonal anti-
VEGFA antibody that has received US Food and Drug Administration
(FDA) approval for use in the treatment of metastatic colorectal cancer
and non-squamous, non–small cell lung cancer in combination with
chemotherapy [4,25–27], as well as metastatic renal cell carcinoma
(combined with interferon-α) and glioblastoma (as a second-line treat-
ment) [http://www.avastin.com/patient/index.html (accessed 30 May
2012)]. Whereas some reports have shown potential beneficial effects
of bevacizumab in the treatment of ovarian epithelial cancer [28–30], very
few studies have investigated its use in the treatment of GCT. Tao et al.
[4] carried out a small retrospective case series and evaluated the clinical
efficacy of bevacizumab with or without concurrent chemotherapy and
found a response rate of 38% and a clinical benefit rate of 63%. This
study was limited, however, by its retrospective nature, its small sample
size, and the variation of treatments administered [4]. One case report
[31] reports symptomatic improvement with bevacizumab combined
with paclitaxel for the treatment of refractory GCT, while another case
report [32] found no clinical improvement with bevacizumab for the
first-line treatment of adult-type GCT. No prospective trial has been
conducted to determine the efficacy of single-agent bevacizumab in the
treatment of GCT.
Amajor factor that has impeded the development of novel therapeutic
approaches for ovarian cancer (including GCT) has been the dearth of
relevant preclinical animal models [10,33,34]. We have recently devel-
oped a genetically engineered mouse model, Ptentm1Hwu/tm1Hwu;
Ctnnb1tm1Mmt/+;Amhr2tm3(cre)Bhr/+ (PCA), in which the phospho-
inositide 3-kinase (PI3K)/protein kinase B (AKT) is derepressed and
the WNT/CTNNB1 pathway is constitutively activated specifically in
granulosa cells [35]. PCA mice develop bilateral GCTs with 100%
penetrance, perinatal onset, rapid growth, and many histopathologic
features of the human disease [35,36]. Importantly, as for the advanced
disease in women, PCA GCTs can form distant metastases and dis-
seminate within the peritoneal cavity [35,36]. In this study, we therefore
used the PCA preclinical model to perform the first controlled study
to investigate the efficacy of anti-VEGFA therapy for the treatment of
GCT disease. We hypothesized that intraperitoneal (i.p.) administration
of anti-VEGFA antibody would effectively reduce tumor growth, reduce
tumor vasculature, and increase tumor cell apoptosis, thereby improving
survival in this murine model of GCT.
Materials and Methods
Animals and Treatments
PCA mice were obtained by selective breeding of the Ptentm1Hwu,
Ctnnb1tm1Mmt, and Amhr2tm3(cre)Bhr parental strains, and genotypes
were verified as previously described [35]. Tumor development in
the PCA model follows a predictable course. At birth, all PCA mice
display nests of dysplastic cells in both ovaries indicating that tumor
growth is initiated perinatally. By 3 weeks of age, GCTs are already
fully formed and continue to grow in a very rapid and aggressive fashion
with abdominal distension becoming apparent by 5 weeks of age and
extreme by 7 weeks. Death due to tumor-related causes inevitably
occurs before 9 weeks of age [35,36]. PCA mice were administered
anti-mouse VEGFA monoclonal antibody clone B20-4.1.1 (provided
by Genentech, Inc, San Francisco, CA) by i.p. injection at 5 mg/kg
(or 0.9% NaCl as a control) once a week beginning at 3 weeks of age.
The mice were sacrificed at 3, 4, 5, 6, 7, and 8 weeks of age and their
ovarian tumors, lungs, and abdominal organs were collected for sub-
sequent use in immunohistochemistry, immunofluorescence, terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays,
Western blot analysis, and histopathology. To evaluate the effects of
variable doses, additional PCAmice received 2.5, 5, or 10 mg/kg of anti-
VEGFA antibody weekly i.p. beginning at 3 weeks of age until 6 weeks
of age, at which point mice were sacrificed and their tumors and organs
were collected as described above (n = 8–16 mice/treatment/time point).
Masses of tumors used in all analyses are indicated in Table W1.
All animal procedures were approved by the Institutional Animal
Care and Use Committee of the University of Montreal and conformed
to the Canadian Council on Animal Care Policy on Humane Care
and Use of Laboratory Animals.
Immunohistochemistry and Immunofluorescence
Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded, 3-μm ovarian tumor sections (n = 4 mice/treatment/time
point) using the VectaStain Elite Avidin-Biotin Complex Kit (Vector
Laboratories, Inc, Burlingame, CA) as directed by the manufacturer.
Sections were probed with proliferating cell nuclear antigen (PCNA)
mouse monoclonal antibody (Cell Signaling Technology, Danvers,
MA, Catalog No. 2586) as directed by the manufacturer, except incu-
bation with the primary antibody (dilution of 1:2000) was performed
for 30 minutes, and incubation with the secondary antibody (biotiny-
lated anti-mouse reagent; Vector Laboratories, Inc; dilution of 1:250)
was done for 10minutes. Sections were also probed with phospho-p44/
42 mitogen-activated protein kinase [MAPK; extracellular signal–
regulated kinases 1 and 2 (ERK1/2)] (Thr202/Tyr204) (D13.14.4E)
XP rabbit monoclonal antibody (mAb; Cell Signaling Technology;
Catalog No. 4370, dilution of 1:200) as directed by the manufacturer.
Staining was done using 3,3′-Diaminobenzidine Peroxidase Sub-
strate Kit (Vector Laboratories, Inc) as directed by the manufacturer.
To determine the number of PCNA-positive cells, four fields per
tumor (one or two tumors per animal; at a ×630 magnification) were
selected at random. From each field, cells were counted within a ran-
domly selected circular area with a 90-μm diameter. For each tumor,
percentage of PCNA-positive cells was calculated by dividing the sum
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of PCNA-positive cells (from all fields) by the total number of cells.
Sections of the same tumors stained with hematoxylin phloxine saffron
stain (HPS) were also evaluated to quantify mitotic figures per ×400 field
as a second measure of cell proliferative activity, as well as to estimate the
extent of tumor necrosis. The area of coagulative necrosis (characterized
by increased eosinophilia and glassy appearance of the area with loss of
cellular details) was evaluated by light microscopy and was estimated
for each tumor as a percentage of the total tumor cross section area. All
slides were evaluated by a board-certified veterinary pathologist.
Immunofluorescence was performed on optimal cutting temperature
compound (OCT)-embedded (Sakura Finetek USA, Inc, Torrance,
CA) frozen ovarian tumors (n = 4 mice/treatment/time point). Samples
were stored at −80°C until they were sectioned (4 μm) and allowed
to dry for 5 hours. The slides were quick-fixed with 100% acetone
(−20°C) for 20 seconds, wrapped in aluminum foil, and stored at
−80°C. When ready, the slides were thawed at room temperature
for 20 minutes, fixed with 100% acetone (−20°C) for 10 minutes, fol-
lowed by 70% ethanol (−20°C) for 5 minutes. The slides were blocked
with 10% goat serum diluted in phosphate-buffered saline (PBS) for
30 minutes and then probed with rat anti-mouse CD31 antibody
(BD Biosciences, Franklin Lakes, NJ; Catalog No. 558736, dilution
of 1:300, overnight at 4°C) and/or fluorescein-labeled Lycopersicon
Esculentum (tomato) lectin (Vector Laboratories, Inc, Catalog No.
FL-1171, dilution of 1:1000, 10 minutes at room temperature) di-
luted in 3% goat serum in PBS. The CD31-probed slides were in-
cubated with the secondary antibody Alexa Fluor 594 goat anti-rat IgG
(Invitrogen, Burlington, ON; Catalog No. A11007, dilution of 1:2000)
for 1 hour at room temperature and diluted in 3% goat serum. The slides
were washed with 1% Triton X-100 (Bioshop Canada, Inc, Burlington,
ON) in PBS for 10 minutes and mounted with VECTASHIELD
mounting medium for fluorescence with 4′,6-diamidino-2-phenylindole
(DAPI; Vector Laboratories, Inc). To evaluate the amount of CD31 sig-
nal, five fields per tumor (at ×200magnification) were selected at random
and ImageJ software was used to quantify the area of signal emitted in
each field. The evaluator was blinded with respect to the ages and treat-
ments received. The double-labeled (CD31 + lectin) slides were used to
confirm the specificity of endothelial cell staining.
TUNEL Assays
TUNEL assays were performed on formalin-fixed, paraffin-embedded,
3-μm ovarian tumor sections (n = 4 mice/treatment/time point) using
the In Situ Cell Death Detection Kit, TMR red (Roche Diagnostics
GmbH,Mannheim, Germany; Catalog No. 12156792910), according
to the manufacturer’s instructions. VECTASHIELDmounting medium
for fluorescence withDAPI (Vector Laboratories, Inc) was used tomount
the slides. To determine the number of positive cells for TUNEL, four
fields per tumor (one or two tumors per animal; at ×630 magnification)
were selected at random. Within each field, a circular area with a 90-μm
diameter was chosen at random to count the number of TUNEL-
positive cells. For each tumor, percentage of TUNEL-positive cells was
calculated by dividing the sum of TUNEL-positive cells (from all fields)
by the total number of cells. A normal healthy ovary containing atretic
follicles was used as a positive control. The evaluator was blinded with
respect to the ages and treatments received.
Western Blot Analysis
Tumor samples from 6-week-old PCA mice were used for Western
blot analysis (n = 4 mice/treatment). Protein extracts were obtained
using T-PER Tissue Protein Extraction Reagent and Halt Protease
and Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher Scien-
tific, Rockford, IL; Catalog Nos 78510 and 78442, respectively)
as described by the manufacturer. Protein concentrations were quan-
tified using the Bradford method. Samples (25 or 50 μg) were resolved
on 7% to 12% sodium dodecyl sulfate–polyacrylamide gels and trans-
ferred to Hybond-P polyvinylidene difluoride (PVDF) Membrane
(GE Amersham, Piscataway, NJ). Blots were probed with primary
antibodies against p44/42 MAPK (ERK1/2) (137F5) rabbit mAb,
phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (D13.14.4E)
XP rabbit mAb, AKT, phospho-AKT (Ser473) (587F11) mouse mAb,
VEGF receptor 2 (55B11) rabbit mAb, phospho–VEGF receptor 2
(Tyr951) (15D2) rabbit mAb, phospho–VEGF receptor 2 (Tyr 1059)
(D5A6) rabbit mAb (Cell Signaling Technology; Catalog Nos 4695,
4370, 9272, 4051, 2479, 4991, and 3817, respectively), and β-actin
(C4) (Santa Cruz Biotechnology, Inc, Santa Cruz, CA; Catalog No.
sc-47778) as directed by the manufacturers. The blots were incubated
with enhanced chemiluminescence (ECL) peroxidase-labeled secondary
antibodies (GE Amersham), and then ECL Plus Western blotting de-
tection reagents (GEAmersham) were used to visualize the protein bands
by chemiluminescence on high-performance chemiluminescence film
(GE Amersham). The signal strengths were quantified using Kodak
1D v.3.6.5 software (Eastman Kodak Company, Rochester, NY).
Statistical Methods
Effects of antibody treatment on tumor size, cell proliferation, cell
apoptosis, CD31 signal intensity, and VEGFA signaling pathway protein
expression were analyzed by analysis of variance, followed by Newman-
Keul or Dunnett post-test to identify differences between specific groups.
P < .05 was considered statistically significant. Prism 4.0a software
(GraphPad Software, Inc, San Diego, CA) was used for analysis.
Results
Anti-VEGFA Therapy Reduces Tumor Burden and Improves
Survival in PCA Mice
To study the efficacy of anti-VEGFA therapy in the PCAmodel, mice
were treated with anti-VEGFA antibody (5 mg/kg, i.p.) once a week
beginning at 3 weeks of age. The mice were sacrificed at 3, 4, 5, 6, 7,
and 8 weeks of age and their ovarian tumors and viscera were collected
for analysis. A dose-response experiment was also conducted using 2.5,
5, and 10mg/kg of anti-VEGFA, i.p., once a week, beginning at 3 weeks
of age until 6 weeks of age, at which point the mice were sacrificed.
PCA mice treated with anti-VEGFA antibody in the dose-response
trial demonstrated that significant effects on tumor burden were
obtained at the 5 mg/kg dose, but no further benefit was obtained
at 10 mg/kg (Figure 1A). In the time course trial, PCA mice showed
significantly reduced ovarian tumor weights at 6 and 7 weeks of age
relative to controls (Figure 1B). Importantly, anti-VEGFA treatment
also extended the survival of treated animals. Whereas all animals
treated with anti-VEGFA antibody survived up to 8 weeks of age,
27.8% (n = 5 of 18) of controls died before 7 weeks of age or had to
be euthanized due to deteriorating health, and no control mice survived
until 8 weeks of age (Figure 1C).
Anti-VEGFA Treatment Reduces Cell Proliferation but Does
Not Affect Apoptosis in PCA GCTs
To determine the cause(s) of reduced GCT size in anti–VEGFA-
treated PCA mice, cell proliferation was assessed by PCNA immuno-
histochemistry and by histologic analysis of mitotic figures. A significant
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decrease in the number of PCNA-positive cells was observed in the anti–
VEGFA-treated group compared to the saline group at 6 weeks of age
(Figure 2A). Likewise, fewer mitoses per high-power field were observed
at 6 weeks of age in the anti–VEGFA-treated group (Figure 2B).
TUNEL assays were performed to determine if increased tumor
cell apoptosis contributed to the decrease in tumor growth in anti–
VEGFA-treated mice. No significant difference in the number of
TUNEL-positive cells in the anti–VEGFA-treated group compared
to the saline group was observed at any age (Figure 3A). Likewise,
although small foci of necrosis were observed in some tumors (par-
ticularly at 6 weeks), anti-VEGFA therapy did not increase the overall
area of necrosis observed in histologic sections (Figure 3B).
Anti-VEGFA Treatment Significantly Reduces Tumor
Microvessel Density in GCTs
To study the effects of anti-VEGFA antibody on angiogenesis in
PCA GCTs, the tumor microvasculature was visualized by immuno-
fluorescence using the endothelial cell marker CD31 (PECAM-1).
Tumors from 6-week-old, anti–VEGFA-treated mice had a markedly
lower microvessel abundance than saline-treated controls, with CD31
signal reduced by more than half in the 5 mg/kg group (Figure 4,
A–C ). Specificity of the CD31 signal for endothelial cells was con-
firmed by double labeling with tomato plant lectin (Figure 4D).
Figure 1. Anti-VEGFA antibody reduces tumor burden and improves
survival of PCAmicewith GCTs. (A) Effects of different doses of anti-
VEGFA on tumor mass in 6-week-old PCA mice (n = 8–16 mice/
treatment/time). Data are shown as means (columns) ± SEM (error
bars). Significant difference from control (saline) is indicated with
one (*P < .05) or two asterisks (**P < .01). Photographs of repre-
sentative tumors are shown below the graph. (B) Time course of
GCTmasswith orwithout weekly anti-VEGFA treatment in PCAmice
(n = 10–26 mice/treatment/time). (C) Survival curves indicating the
proportion of experimental mice surviving at the indicated times
(n = 4–18 mice/treatment/time). Anti–VEGFA-treated mice were
sacrificed for humane reasons at 3 days past the 8-week time point.
Figure 2. Anti-VEGFA antibody reduces cell proliferation in GCTs
from PCAmice. (A) Graph depicting the proportion (as percentage)
of PCNA-positive cells in PCA mice administered anti-VEGFA anti-
body or saline (control), n = 4 mice/treatment/time point. Repre-
sentative photomicrographs of PCNA-stained tumors are shown
below the graph at a ×630 magnification. (B) Evaluation of mitotic
indices in the tumors described in A. Error bars = SEM. Significant
difference from control (P < .05) is indicated with an asterisk.
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Intracellular Signaling Is Altered in Tumors from PCA
Mice Treated with Anti-VEGFA Antibody
To identify potential alterations in intracellular signaling activity
downstream of VEGFR2 caused by anti-VEGFA treatment, activity
levels of the p44/42 MAPK (ERK1/2) and the PI3K/AKT signaling
pathways were evaluated by Western blot analysis. Levels of phospho-
p44/42 MAPK (Thr202/Tyr204) were significantly lower in GCTs
from 6-week-old PCA mice that had received as little as 2.5 mg/kg of
anti-VEGFA antibody, as was the ratio of phosphorylated-to-total
p44/42 MAPK (Figure 5, A and B), indicative of decreased MAPK
signaling activity. Immunohistochemistry was performed to deter-
mine the cell population(s) within the tumors in which this decrease
occurred, which showed that granulosa, stromal, and endothelial cells
(identified on the basis of morphologic characteristics) all appeared to
be affected (Figure 5C).
Contrary to the MAPK pathway, no significant difference was
found in the expression of AKT or phospho-AKT between the various
anti–VEGFA-treated groups and the saline group (Figure 6, A and B),
suggesting that activity of the PI3K/AKT pathway was not altered by
treatment. Activation of VEGFR2 was also studied, but tyrosine phos-
phorylation of the receptor at sites 951 and 1059 could not be detected
in either the anti–VEGFA-treated or the control groups (not shown).
Discussion
Few therapeutic options exist for advanced stage and recurrent GCT,
and none of the widely used chemotherapeutic regimens has been
rigorously evaluated with regard to its effectiveness [11,13,37,38].
The development of validated adjuvant chemotherapies for GCT is
therefore of paramount importance.Whereas angiogenesis (i.e., VEGFA)
has been proposed as a therapeutic target for GCT [4,17,18,31,32],
clinical investigations of anti-VEGFA therapies have so far been limited
to small-scale retrospective studies and case reports and have yielded
limited insight [4,31,32]. In this report, we used the recently developed
PCA mouse model, which develops an ovarian cancer that mimics
many of the histologic and biologic aspects of advanced human
GCT [35,36], to investigate the efficacy of an anti-VEGFA antibody
analogous to bevacizumab. Our results in this preclinical model clearly
show that anti-VEGFA therapy extends survival and significantly
slows tumor growth. These findings therefore support the prospective
investigation of anti-VEGFA therapy for the adjuvant treatment of
GCT in women.
Our findings indicate that the main mechanism by which the anti-
VEGFA antibody slowed tumor growth was inhibition of tumor cell
proliferation rather than induction of apoptosis. Proliferation was pre-
sumably inhibited, at least in part, by reduced microvessel density,
resulting in decreased delivery of nutrients and growth factors to tumor
Figure 3. Anti-VEGFA antibody has no significant effect on apop-
tosis or tumor necrosis in GCTs from PCAmice. (A) Graph depicting
the proportion (as percentage) of TUNEL-positive cells in PCA mice
administered anti-VEGFA antibody or saline (control), n = 4 mice/
treatment/time point. (B) Evaluation of extent of tumor necrosis
(as percentage of total surface in histologic sections) in the tumors
described in A. Error bars = SEM.
Figure 4. Anti-VEGFA antibody significantly reduces microvessel
density in GCTs from 6-week-old PCA mice. (A) Graph depicting
CD31 immunofluorescence signal strengths in GCTs from 6-week-
old PCA mice that received the indicated treatments (n = 4 animals/
treatment). Data are shown as means (columns) ± SEM (error bars).
Significant difference from control (saline) is indicated with one
(*P < .05) or two asterisks (**P < .01). (B) Representative photo-
micrograph (originalmagnification,×200) depicting CD31 fluorescent
signal in the GCT of a 6-week-old PCA mouse. CD31-specific signal
is red; nuclei are counterstained with DAPI (blue). (C) As per B, show-
ing a tumor from an anti–VEGFA-treated mouse. (D) As per B, except
endothelial cells were labeled with tomato plant lectin (green) in
addition to CD31 immunolabeling; original magnification, ×630.
Overlap in lectin and CD31 signals appears yellow and confirms the
specific labeling of endothelial cells by CD31.
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cells. However, our results also suggest that the anti-VEGFA therapy
may have acted directly upon the tumor cells themselves to inhibit
proliferation. Indeed, apparent lower levels of phosphorylation (i.e.,
activity) of the VEGFA receptor signaling effector MAPK were ob-
served not only in endothelial cells but also in tumor cells from anti–
VEGFA-treated mice. As MAPK signaling is thought to mediate the
pro-proliferative actions of VEGFA [39,40], this suggests that the
anti-VEGFA treatment acted to sequester pro-proliferative VEGFA
from the tumor cells in the PCA model. This would be entirely con-
sistent with the well-established role of VEGFA as a granulosa cell
growth factor in the context of normal ovarian follicle development
[41,42] and would indicate that GCT cells retain a certain dependence
on VEGFA as a proliferative signal even after oncogenic transforma-
tion. VEGFA also signals through the PI3K/AKT pathway, whose
activity is associated with the antiapoptotic effects of VEGFA [43,44].
Anti-VEGFA therapy had no effect on tumor cell apoptosis in the PCA
model and did not alter AKT phosphorylation (i.e., activity). VEGFA/
AKT cytoprotective signaling would therefore not appear to be relevant
to the pathogenesis of GCT, at least in the PCA model.
The effect of the anti-VEGFA antibody on GCTmicrovessel density
in the PCA model concurs with findings from other studies that eval-
uated the effect of analogous anti-VEGFA antibodies on vascular
growth. Korsisaari et al. [27] found a significant reduction in vessel
density after 3 weeks of administration of anti-VEGFA mAb G6-31
in a murine model of intestinal adenoma. Likewise, Borgström et al.
[45] found complete inhibition of angiogenesis in microtumors with
administration of anti-VEGF antibody A4.6.1 in a tumor xenograft
study of human prostate carcinoma. In past studies, anti-VEGFA ther-
apy has been found to reduce tumor microvessel density, decrease per-
meability, increase tumor pericyte coverage, and stabilize the basement
membrane, which all contribute to forming a more normalized tumor
vasculature [46,47]. In consequence, tumor hypoxia and interstitial
fluid pressure are reduced, which allows improved delivery of chemo-
therapy to the tumor, as observed in clinical trials [19,47,48]. If this
holds true for GCT as well, another benefit of anti-VEGFA therapy
may be to enhance the effects of other chemotherapeutic agents when
used in the context of combinatorial therapy. The PCA mouse model
Figure 5. Anti-VEGFA antibody significantly reduces MAPK activa-
tion in GCTs from 6-week-old PCAmice. (A) Graph depicting expres-
sion of MAPK, phospho-MAPK, and phospho-MAPK/total MAPK
ratio in tumors from 6-week-old PCA mice that received the indi-
cated treatments. Data are densitometric quantification of signals
obtained by Western blot analysis (n = 4 per treatment). Data are
shown as means (columns) ± SEM (error bars). Significant differ-
ence from control (saline) is indicated with one (*P < .05) or two
asterisks (**P < .01). (B) Representative Western blot images from
the analyses shown in A (n = 2 samples/treatment). β-Actin was
used as a loading control. (C) Immunohistochemical analysis of
phospho-MAPK expression in tumors from 6-week-old PCA mice
treated with saline control or anti-VEGFA (5 mg/kg); original mag-
nification, ×400.
Figure 6. Anti-VEGFA antibody has no significant effect on AKT
activation in GCTs from 6-week-old PCA mice. (A) Graph depict-
ing expression of AKT, phospho-AKT, and phospho-AKT/total
AKT ratio in tumors from 6-week-old PCAmice that received the indi-
cated treatments. Data are densitometric quantification of signals
obtained by Western blot analysis (n = 4 per treatment). Data
are shown as means (columns) ± SEM (error bars). (B) Representa-
tive Western blot images from the analyses shown in A (n = 2
samples/treatment). β-Actin was used as a loading control.
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may prove useful to test this hypothesis, as well as for the subsequent
development of combinatorial treatment schemes.
In summary, this study shows that monotherapy with anti-VEGFA
antibody is effective at suppressing tumor growth and extending sur-
vival in the PCAmodel of GCT. Targeting VEGFA reduced tumor cell
proliferation and microvascular density, which could sensitize GCTs
to the effects of other chemotherapeutic agents. On the basis of our
results, we conclude that anti-VEGFA therapy shows great potential
in the adjuvant treatment of GCT.
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Table W1.Masses of GCTs Used for (A) Immunohistochemistry, Mitotic Figures, TUNEL Assay,
Percentage of Necrosis, (B) Tumors from 6-Week-Old Mice Used for Immunofluorescence, and
(C) Tumors from 6-Week-Old Mice Used for Western Blot.
(A)
Age (Weeks) Treatment Received Tumor Mass (g, Mean ± SEM)
3 – 0.00466 ± 0.000444
4 0.9% NaCl 0.0515 ± 0.00414
4 5 mg/kg anti-VEGFA 0.0618 ± 0.00936
5 0.9% NaCl 0.178 ± 0.0564
5 5 mg/kg anti-VEGFA 0.0830 ± 0.0163
6 0.9% NaCl 0.723 ± 0.258
6 2.5 mg/kg anti-VEGFA 1.08 ± 0.127
6 5 mg/kg anti-VEGFA 0.307 ± 0.151
6 10 mg/kg anti-VEGFA 0.223 ± 0.0485
(B)
Treatment Received Tumor Mass (g, Mean ± SEM)
0.9% NaCl 1.39 ± 0.238
2.5 mg/kg anti-VEGFA 1.08 ± 0.123
5 mg/kg anti-VEGFA 0.322 ± 0.0223
10 mg/kg anti-VEGFA 0.223 ± 0.0485
(C)
Treatment Received Tumor Mass (g, Mean ± SEM)
0.9% NaCl 1.39 ± 0.238
2.5 mg/kg anti-VEGFA 1.09 ± 0.127
5 mg/kg anti-VEGFA 0.322 ± 0.0223
10 mg/kg anti-VEGFA 0.223 ± 0.0485
